Cost-effectiveness analysis of screening for peripheral artery disease in patients with coronary artery disease in China: A Markov model

Yuanming Xing,Yulan Qiu,Luting Yang,Zuyi Yuan,Yan Wang

International Journal of Cardiology（2023）

引用 0|浏览10

暂无评分

摘要

•ABI screening for PAD was not cost-effective for patients with CAD in China.•The reduction in all-cause mortality related to rivaroxaban most affected the ICER.•Policy-guided cost changes for rivaroxaban could easily resolve this issue in China.

查看译文

关键词

Coronary artery disease,Peripheral artery disease,Ankle brachial index,Cost-benefit analysis,Rivaroxaban

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要